Last updated on August 9, 2024
Akums Drugs IPO Description – Founded in 2004, Akums Drugs and Pharmaceuticals has emerged as a prominent player in the pharmaceutical contract development and manufacturing (CDMO) sector, offering an extensive array of pharmaceutical products and services in India and internationally. Distinguished as one of India’s leading CDMOs, Akums holds intellectual property for numerous manufacturing processes for its formulations.
The company has manufactured 4,146 commercialized formulations across over 60 dosage forms. The company manufactured formulations for 26 of the leading 30 pharmaceutical companies in terms of sales in India. The CDMO business, operates 10 manufacturing units, with a cumulative formulations manufacturing capacity of 49.23 billion units annually, as of 31 March 2024.
The company has presence in 60 countries worldwide such as Vietnam, Philippines, Peru, Myanmar, Cambodia, Latvia, Myanmar, Tanzania, and Kenya, among others. As of 31 March 2024, key clients for the CDMO business include Alembic Pharmaceuticals, Alkem Laboratories, Cipla, Dabur India, Dr. Reddy’s Laboratories, Mankind Pharma, MedPlus Health Services, Natco Pharma, Sun Pharmaceutical Industries, and Amishi Consumer Technologies (The Mom’s Co), among others.
Promoters of Akums Drugs – Sanjeev Jain, Sandeep Jain, and Akums Master Trust
Table of Contents
Akums Drugs IPO Details
| Akums Drugs IPO Dates | 30 July – 1 August 2024 |
| Akums Drugs Issue Price | INR 646 – 679 per share (Employee Discount – INR 64 per share) |
| Fresh issue | INR 680 crore |
| Offer For Sale | 1,73,30,435 shares (INR 1,119.55 – 1,176.74 crore) |
| Total IPO size | INR 1,799.55 – 1,856.74 crore |
| Minimum bid (lot size) | 22 shares (INR 14,938) |
| Face Value | INR 2 per share |
| Retail Allocation | 10% |
| Listing On | NSE, BSE |
Akums Drugs Financial Performance
| Â | FY 2022 | FY 2023 | FY 2024 |
| Revenue | 3,671.89 | 3,654.82 | 4,178.18 |
| Expenses | 3,874.95 | 3,475.93 | 4,231.45 |
| Net income | (250.87) | 97.82 | 0.79 |
| Margin (%) | (6.83) | 2.68 | 0.02 |
Akums Drugs Offer News
- Akums Drugs IPO: Contract Manufacturer Aims for Listing in 2024
- Akums Drugs RHP
- Akums Drugs DRHP
- ASBA IPO Forms
- Live IPO Subscription Status
- IPO Allotment Status
Akums Drugs Valuations & Margins
| FY 2022 | FY 2023 | FY 2024 (Post-Issue)* | |
| EPS | (17.02) | 6.64 | 0.05 |
| PE Ratio | – | – | 12,053.22 – 12,668.94 |
| FY 2022 | FY 2023 | FY 2024 | |
| RONW (%) | (40.60) | 13.23 | (0.57) |
| NAV | 42.20 | 48.66 | 48.13 |
| ROCE (%) | (18.89) | 24.60 | 3.37 |
| EBITDA (%) | (1.87) | 10.38 | 3.73 |
| Debt/Equity | 0.58 | 0.75 | 0.69 |
Akums Drugs IPO GMP Today (Daily Trend)
| Date | Day-wise IPO GMP | Kostak | Subject to Sauda |
| 5 August 2024 | 100 | – | 1,500 |
| 3 August 2024 | 130 | – | 2,100 |
| 2 August 2024 | 150 | – | 2,300 |
| 1 August 2024 | 180 | – | 2,800 |
| 31 July 2024 | 193 | – | 3,000 |
| 30 July 2024 | 193 | – | 3,000 |
| 29 July 2024 | 180 | – | 2,750 |
| 27 July 2024 | 175 | – | 2,650 |
| 26 July 2024 | 150 | – | 2,500 |
Akums Drugs IPO Objectives
The company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:
- Repayment/prepayment of all or certain borrowings of the company – INR 159.91 crore
- Repayment/prepayment of all or certain borrowings of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited – INR 227.09 crore
- Funding incremental working capital requirements of the company – INR 55 crore
- Pursuing inorganic growth initiatives through acquisitions
- General corporate purposes
Akums Drugs – Comparison With Listed Peers
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Akums Drugs and Pharmaceuticals | 12,668.94 | 0.05 | (0.57) | 48.13 | 4,178.18 |
| Divi’s Laboratories | 74.99 | 60.27 | 11.79 | 511.21 | 7,845.00 |
| Suven Pharma | 69.54 | 11.80 | 14.64 | 80.56 | 1,051.35 |
| Gland Pharma | 42.45 | 46.89 | 8.85 | 529.65 | 5,664.72 |
| Torrent Pharma | 60.20 | 48.94 | 24.15 | 202.57 | 10,728.00 |
| Alkem Laboratories | 34.18 | 150.19 | 17.41 | 862.46 | 12,667.58 |
| Eris Lifesciences | 34.95 | 28.79 | 15.16 | 190.12 | 2,009.14 |
| JB Chemicals | 51.38 | 34.85 | 18.90 | 188.37 | 3,484.18 |
| Mankind Pharma | 44.65 | 47.68 | 20.43 | 233.73 | 10,334.77 |
| Innova Captab | 29.91 | 18.66 | 11.35 | 145.20 | 1,081.31 |
Akums Drugs IPO Dates & Listing Performance
| IPO Opening Date | 30 July 2024 |
| IPO Closing Date | 1 August 2024 |
| Finalization of Basis of Allotment | 2 August 2024 |
| Initiation of refunds | 5 August 2024 |
| Transfer of shares to demat accounts | 5 August 2024 |
| Akums Drugs IPO Listing Date | 6 August 2024 |
| Opening Price on NSE | INR 725 per share (up 6.77%) |
| Closing Price on NSE | INR 796.25 per share (up 17.27%) |
Akums Drugs IPO Reviews – Subscribe or Avoid?
Angel One –
Anand Rathi –
Antique Stock Broking –
Arihant Capital –
Ashika Research – Not rated
BP Wealth – Subscribe
Capital Market – Subscribe
Canara Bank Securities – Subscribe
Choice Broking –
Dalal & Broacha –
Elite Wealth – Not rated
GCL Broking –
Geojit –
GEPL Capital – Subscribe
Hem Securities – Subscribe
ICICIdirect –
Indsec – Subscribe
Jainam Broking – Subscribe for long term
DR Choksey –
LKP Research –
Marwadi Financial – Subscribe
Systematix Shares –
Mehta Equities – Subscribe for long term
Nirmal Bang –
Reliance Securities –
Sushil Finance –
Samco Securities – Subscribe for long term
SBI Securities – Subscribe for long term
SMC Global – 2/5
SMIFS –
Swastika Investmart – Subscribe
Ventura Securities – Subscribe
Akums Drugs Offer Lead Manager
ICICI SECURITIES LIMITED
ICICI Venture House Appasaheb Marathe Marg Prabhadevi
Mumbai 400 025 Maharashtra, India
Phone: +91 22 6807 7100
Email:Â [email protected]
Website: www.icicisecurities.com
Akums Drugs Offer Registrar
LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai 400 083, Maharashtra, India
Tel:Â (+91) 81081 14949
E-mail: [email protected]
Website:Â www.linkintime.co.in
Akums Drugs Contact Details
AKUMS DRUGS AND PHARMACEUTICALS LIMITED
Plot no. 131 to 133, Block C, Mangolpuri, Ind. Area,
Phase 1, Delhi – 110 083, India
Phone:Â +91 11 6904 1000
Email: [email protected]
Website: www.akums.in
Akums Drugs IPO FAQs
How many shares in Akums Drugs IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 75%, NII – 15%, and Retail – 10%.
How to apply for an Akums Drugs Public Offer?
The best way to apply for Akums Drugs public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Akums IPO GMP today?
Akums Drugs IPO GMP today is INR 100 per share.
What is Akums Drugs kostak rate today?
Akums Drugs kostak rate today is INR NA per application.
What is Akums Drugs Subject to Sauda rate today?
Akums Drugs Subject to Sauda rate today is INR 1,500 per application.
